Doesn’t it seem like a lifetime ago that health IT companies all over the world were readying to fly to Orlando for HIMSS20? To say that much has happened – and much has changed – since then is, unquestionably, an understatement.
One thing the COVID-19 pandemic hasn’t changed is the potential of AI to improve healthcare and health costs. Another is my delight in sharing the robust conversation I had with three healthcare leaders about the ways AI is helping primary care physicians achieve the Triple Aim.
ICYMI, I hosted a virtual AI Fireside Chat – originally scheduled to take place at HIMSS20 and recorded on March 10 – with:
- Josh Newman, MD, Salesforce Chief Medical Officer
- Bharat Rao, Partner/Leader Data Analytics, KPMG Healthcare Life Sciences
- Aneesh Chopra, CareJourney President and former US CTO
Watch the highlights of our conversation now.
We started the conversation with the question, How far has AI in healthcare progressed since HIMSS19? Josh Newman of Salesforce shared his perspective that there has been significant progress in terms of life sciences, imaging, diagnosis around imaging and the claims analysis some payers are doing. There has been less progress, he said, in customer relationship management (CRM), engagement, care coordination and patient navigation.
Aneesh Chopra discussed the "considerable progress in shots on goal" with more organizations investing in use cases. He offered a challenge to continued progress saying so many organizations have only a fragment of the patient journey in hand, which complicates the creation and use of models.
My second question was, What are some ways AI can help primary caregivers improve the cost of care without sacrificing quality?
Bharat Rao shared his view that the number one use case for AI is the 95 percent of care that is routine, such as diabetic care. Primary care physicians are expected to keep track of a diabetic patient’s blood sugar and blood pressure, eye and foot exams, and more. Knowing that’s not easy, he suggested AI can play a great role in helping primary care providers manage the multi-factor care that’s often needed to manage chronic diseases.
In response to my third question, What are some ‘gateway drugs’ to advanced forms of AI in provider organizations that will improve the Triple Aim?, Chopra shared a staggering and true story about a successful program to help prediabetics prevent the progression to diabetes. Rather than relate the story right here, I invite you to watch the video. He concluded the story with his perspective that matching population segments to the interventions that matter is the next decade of work.
We wrapped up the discussion with our final thoughts on AI and its role in future healthcare costs and Newman’s suggestion that we have another fireside chat in 2021 when we answer the question, How far have we come with social determinants of health (SDoH) since HIMSS19 and HIMSS20? I, for one, can’t wait.
In the meantime, I invite you to watch the AI Fireside Chat.